Logo

Teva's Austedo (deutetrabenazine) Receives the NMPA's Approval to Treat Chorea Associated with Huntington's Disease and Tardive Dyskinesia in Adults

Share this
Teva's Austedo (deutetrabenazine) Receives the NMPA's Approval to Treat Chorea Associated with Huntington's Disease and Tardive Dyskinesia in Adults

Teva's Austedo (deutetrabenazine) Receives the NMPA's Approval to Treat Chorea Associated with Huntington's Disease and Tardive Dyskinesia in Adults

Shots:

  • Austedo has received its second approval from NMPA (prior CFDA) following the US FDA’s approval to treat tardive dyskinesia and chorea associated with Huntington’s disease in adults
  • The approval was completed within four months post granting of Priority Review by the NMPA and has also placed Austedo on the List of Overseas New Drugs Urgently Needed in Clinical Settings (the First Batch)
  • Austedo is a vesicular monoamine transporter 2 (VMAT2) inhibitor and will be commercialized by Teva in China following the recent launch of Treanda

Click here to read full press release/ article | Ref: Teva | Image: Behnace


Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions